




Speakers Booklet

E-workshop (via WebEx) on Health Technology Assessment 12-14 May 2020	
	<p>Dr Aw holds a PhD in Biology and Rochelle is currently a Research Associate in the Future Vaccine Manufacturing Research Hub within the Department of Chemical Engineering at Imperial College London. Her research focuses on optimising the recombinant expression platform, <i>Pichia pastoris</i>, for the production of vaccine targets. She has over a decade of experience working on the yeast <i>Pichia pastoris</i> including industrial placements.</p>
Dr Rochelle Aw	
	<p>Ms. Eyermann is an Associate at CHAI focusing on both innovation and supplier sustainability. She is currently leading CHAI's work on COVID-19 vaccine demand forecasting. Elizabeth holds a BA in Biology and Diplomatic History from the University of Pennsylvania and previously worked as a life sciences strategy consultant.</p>
Ms Elizabeth Eyermann	
	<p>Mr Hayman is a Research Associate at DCVMN International working on data analysis, market intelligence and online training tools. Benoit holds a BSc in economics from the University of Otago and is completing his MSc at the University of Lausanne. He has two years' experience teaching economics, finance and statistics.</p>
Mr Benoit Hayman	



Mr Chand Mehta

Mr Mehta leads CHAI's strategy engagements with Indian vaccine manufacturers, and is the antigen lead for rotavirus, typhoid and meningitis vaccines. Chand is also responsible for driving the global agenda on supplier sustainability. Previously, he worked as a Business Analyst at Novartis in several roles across finance and marketing. He holds a BA and MSc from Oxford University in Economics & Management and Contemporary Indian Studies.



Dr Parisa Meysami

Dr Meysami holds a PhD in Medical Virology. Currently, Parisa is working as a Research Associate in the Berger laboratory that is a part of the EPSRC-funded Innovative Vaccine Manufacturing Hub at the University of Bristol.

Her research focuses on the use of advanced state-of-the-art baculovirus-based protein production tools (MultiBac) in combination with synthetic biology approaches, structural biology, cell biology and imaging techniques to develop next-generation vaccine candidates to combat emerging infectious disease.



Ms Fruzsina Rabi

Ms Rabi is the Manager of Bristol University's largest Eukaryotic Protein Production Facility. Since joining the School of Biochemistry in 2015, Fruzsina has worked on numerous projects expressing proteins and multiprotein complexes in insect cell culture for structural and functional studies. Using the MultiBac baculovirus system, she provides services and training in protein expression and purification for members of both academia and industry.